Granisetron shows no pro-arrhythmic effect in normal subjects during or after exercise in a hot environment

Aviation Space and Environmental Medicine

Volumn 67, Issue 8, 1996, Pages 759-761

  Gray, G W ^a   Mclellan, T M ^a   Ducharme, M B ^a  

^a DEF AND CIV INST OF ENVIRON MED   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GRANISETRON;

ADULT; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROCARDIOGRAPHY MONITORING; EXERCISE; HEART ARRHYTHMIA; HEAT TOLERANCE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; SEROTONIN RELEASE; THERMOREGULATION; VOMITING;

ADMINISTRATION, ORAL; BODY TEMPERATURE REGULATION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY, AMBULATORY; EXERCISE; GRANISETRON; HEART; HEAT; HUMANS; MALE; REFERENCE VALUES; SEROTONIN ANTAGONISTS;

EID: 0029738511     PISSN: 00956562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Aapro MS. 5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991; 42:551-68.
2. Andrews PLR. 5-HT3 receptor antagonists and anti-emesis. In: 5-HT3 receptor antagonists. King FD, Jones BJ, Sanger GJ, eds. Boca Raton, FL: CRC Press, 1994.
3. Ballard HS, Bottino G, Bottino J. Ondansetron and chest pain. Lancet 1992; 340:1107.
4. Bourke JP. Does granisetron share the cardiac arrhythmogenic potential of other 5-HT3 receptor antagonists?. Proc. ECCO, 1993:18-21.
5. Castle WM, Cunningham K, Kanarek BB. Ondansetron is not associated with vascular events, thrombocytopenia or renal failure. Ann. Oncol. 1992; 9:773-4.
6. Childs AM, Coates AS, Cox KM, Mainwaring PM. Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and Ondansetron. Ann. Oncol. 1994; 5:98-9.
7. Chiu EKW, Liang R, Lie A, Todd D, Chan TK. Comparison of Ondansetron with metoclopromide in the control of emesis induced by moderately emetogenic chemotherapy used for lymphoma and leukemia patients. Drug Invest 1994; 8:104-9.
8. Coates AS, Childs A, Cox K, Forsyth C, Joshua DE, McNeil, Grygiel JJ. Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron. Ann Oncol. 1992; 3:719-22.
9. PDA 1993. Transcripts of proceedings from the 40th meeting of the Gastrointestinal Drugs Advisory Committee, Department of Health and Human Services, Public Health Service, Food and Drug Administration, Rockville, Maryland.
10. McLellan TM, Ducharme MB. Influence of granisetron on thermorégulation during exercise in the heat. Aviat Space Environ Med 1996; 67:453-7.
11. Williams AJ, Stinson JC, Pears JS. 24 hour ambulatory ECG recordings in healthy volunteers. What is pathological? Can J Physiol Pharmacol 1994; 72:(Suppl 1) 606.
12. Yarker EY, McTavish M. Granisetron: an update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy. Drugs 1994; 48:761-93.